Ethylbenzene

Ethylbenzene

SCHEMBL798422

CCCCCCC.CCc1ccccc1

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.74
DNM1 Q05193 2/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
EPHX2 P34913 2/20 0.53
MAPK1 P28482 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
PKM P14618 1/20 0.53
SIGMAR1 Q99720 1/20 0.52
HTT P42858 2/20 0.52
KCNH2 Q12809 1/20 0.52
CETP P11597 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetradecane SCHEMBL28192190 1.00 TP53 (0.74) TP53DNM1MEN1KMT2AEPHX2
Ethylbenzene SCHEMBL3882350 1.00 TP53 (0.74) TP53DNM1MEN1KMT2AEPHX2
Hexadecane SCHEMBL10591100 1.00 TP53 (0.74) TP53DNM1MEN1KMT2AEPHX2
Decane SCHEMBL28219479 1.00 TP53 (0.74) TP53DNM1MEN1KMT2AEPHX2
Decane SCHEMBL10591097 1.00 TP53 (0.74) TP53DNM1MEN1KMT2AEPHX2
Ethylbenzene SCHEMBL11070302 0.97 TP53 (0.78) TP53DNM1MEN1KMT2AEPHX2
Ethylbenzene SCHEMBL22634197 0.97 TP53 (0.78) TP53DNM1MEN1KMT2AEPHX2
Ethylbenzene SCHEMBL14632730 0.92 TP53 (0.78) TP53DNM1MEN1KMT2AEPHX2
Ethylbenzene SCHEMBL27417994 0.91 TP53 (0.61) TP53DNM1MEN1KMT2AEPHX2
Ethylbenzene SCHEMBL28886241 0.89 TP53 (0.58) TP53DNM1MEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118239931-A As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-06-25 CN disclosed
CN-114269432-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN disclosed
EP-4301756-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2024-01-10 EP disclosed
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) 2023-03-23 US disclosed
EP-4027995-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-07-20 EP disclosed
EP-3976179-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-04-06 EP disclosed
WO-2021050964-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2021-03-18 WO disclosed
WO-2020239951-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO disclosed
EP-3140309-A1 3-OXO-TETRAHYDRO-FURO[3,2-B]PYRROL-4(5H)-YL) DERIVATIVES I Grünenthal GmbH (DE) 2017-03-15 EP disclosed
EP-1926721-B1 THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS MSD ITALIA SRL (IT) 2016-05-04 EP disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed
EP-2398323-A1 NOVEL HETERO PYRROLE ANALOGS ACTING ON CANNAPINOID RECEPTORS University of Connecticut (US) 2011-12-28 EP disclosed
EP-2205562-B1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-03-16 EP disclosed
WO-2010104488-A1 NOVEL HETERO PYRROLE ANALOGS ACTING ON CANNAPINOID RECEPTORS UNIVERSITY OF CONNECTICUT (US) 2010-09-16 WO disclosed
EP-2205562-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
WO-2009040288-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed
EP-1926721-A2 THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2008-06-04 EP disclosed
WO-2007029035-A2 THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-03-15 WO disclosed
EP-1743333-A1 METAL CHELATES AND THEIR USE IN OPTICAL RECORDING MEDIA HAVING HIGH STORAGE CAPACITY CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) 2007-01-17 EP disclosed
WO-2005106868-A1 METAL CHELATES AND THEIR USE IN OPTICAL RECORDING MEDIA HAVING HIGH STORAGE CAPACITY CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092892-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 TP53 4404/4885DNM1 2401/4885MEN1 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.